Top Markets
Coin of the day
Eli Lilly Eli Lilly

Eli Lilly

LLY
Classifica tra le azioni #15
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals... Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Prezzo delle azioni
$910.55
Capitalizzazione di mercato
$860.30B
Variazione (1 giorno)
0.44%
Variazione (1 anno)
5.28%
Paese
US
Scambia Eli Lilly (LLY)

Categoria

Rapporto P/S per Eli Lilly (LLY)
Rapporto P/S al March 2026 TTM: 14.26
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Eli Lilly, il rapporto P/S attuale (TTM) è 14.26. Alla fine del 2024, era pari a 15.44.
Storico del rapporto P/S per Eli Lilly da 2000 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
2026 (TTM) 14.26 -3.73%
2025 14.81 -4.08%
2024 15.44 0.47%
2023 15.36 26.14%
2022 12.18 30.93%
2021 9.30 41.33%
2020 6.58 16.73%
2019 5.64 1.90%
2018 5.53 24.39%
2017 4.45 16.60%
2016 3.82 -18.23%
2015 4.67 19.45%
2014 3.91 58.51%
2013 2.46 -1.49%
2012 2.50 31.23%
2011 1.91 13.53%
2010 1.68 -6.52%
2009 1.80 -16.98%
2008 2.16 -30.75%
2007 3.12 -13.42%
2006 3.61 -14.14%
2005 4.20 -5.31%
2004 4.44 -26.20%
2003 6.01 -2.75%
2002 6.18 -15.65%
2001 7.33 -20.80%
2000 9.26 0.00%
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
4.96 -65.20%
GB
6.18 -56.66%
US
6.35 -55.45%
US
5.18 -63.69%
CH
4.40 -69.16%
US